pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. bluebird had set an initial price of $1.8 market and will wind down in Europe. .

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

pharmaphorum

JUNE 23, 2022

Novartis has shouldered its way into the in vivo gene editing category via a deal with US biotech Precision BioSciences, focused on a therapy for sickle cell disease (SCD). Precision Bio will take the ARCUS candidate through early-stage discovery, with Novartis taking over for the research, development, manufacturing and commercial stages.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

pharmaphorum

JANUARY 5, 2023

Stéphane Bancel, chief executive officer at Moderna, said: “With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing.”. The post Boost for mRNA as Moderna to acquire OriCiro for $85 million appeared first on.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Drug Discovery World

JULY 24, 2023

The Defense Advanced Research Projects Agency (DARPA) has announced that Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has been awarded a four-year contract worth up to $18 million to reimagine how to manufacture complex therapeutic proteins.

Protein 52

Protein Manufacturing Gene Sequencing Production 52

pharmaphorum

OCTOBER 12, 2022

The neoantigens are selected based on gene sequencing of either a tumour biopsy or a blood sample, with an individual vaccine tailored to the patient manufactured and administered in a matter of weeks.

Vaccination 105

Vaccination Vaccine Gene Sequencing RNA 105

Drug Discovery World

AUGUST 5, 2022

Evonetix is reimaging biology by developing a different approach to gene synthesis. Evonetix believes this will break dependence on the service provider approach giving users the power to prepare gene sequences rapidly in their own laboratories. Why enzymatic synthesis? The work continues. “We

DNA 52

DNA Engineer Gene Sequencing Gene 52